[1]Wherry EJ，Ha SJ，Kaech SM，et al.Molecular signature of CD8+，T cell exhaustion during chronic viral infection［J］.Immunity，2007，27(4)：670-684.
[2]Wherry EJ.T cell exhaustion［J］.Nature Immunology，2011，12(6)：492.
[3]Villadolid J，Amin A.Immune checkpoint inhibitors in clinical practice：Update on management of immune-related toxicities［J］.Translational Lung Cancer Research，2015，4(5)：560.
[4]Wang J，Yuan R，Song W，et al.PD-1，PD-L1（B7-H1) and tumor-site immune modulation therapy：The historical perspective［J］.Journal of Hematology & Oncology，2017，10(1)：34.
[5]Topalian SL，Hodi FS，Brahmer JR，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］.New England Journal of Medicine，2012，366(26)：2443.
[6]Topalian SL，Sznol M，Mcdermott DF，et al.Survival，durable tumor remission，and long-term safety in patients with advanced melanoma receiving nivolumab［J］.J Clin Oncol，2014，32(10)：1020.
[7]Hamid O，Robert C，Daud A，et al.Safety and tumor responses with lambrolizumab（Anti-PD-1) in melanoma［J］.New England Journal of Medicine，2013，369(2)：134.
[8]Le DT，Durham JN，Smith KN，et al.Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade［J］.Science，2017，357(6349)：409.
[9]Fisher TS，Kamperschroer C，Oliphant T，et al.Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity［J］.Cancer Immunology Immunotherapy Cii，2012，61(10)：1721-1733.
[10]Curti BD，Kovacsovicsbankowski M，Morris N，et al.OX40 is a potent immune-stimulating target in late-stage cancer patients［J］.Cancer Research，2013，73(24)：7189-7198.
[11]Schaer DA，Hirschhorn-Cymerman D，Wolchok JD.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy［J］.Journal for Immunotherapy of Cancer，2014，2(1)：7.
[12]Jha V，Workman CJ，Mcgaha TL，et al.Lymphocyte Activation Gene-3（LAG-3) negatively regulates environmentally-induced autoimmunity［J］.PLoS One，2014，9(8)：e104484.
[13]Wang YW，Shi DB，Liu YM，et al.Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma［J］.Journal of Cancer Research & Clinical Oncology，2014，140(8)：1271-1281.
[14]Zhang YC，Guo LQ，Chen X，et al.The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells［J］.Molecular Medicine Reports，2015，11(2)：797-804.
[15]Goldberg MV，Drake CG.LAG-3 in cancer immunotherapy［J］.Current Topics in Microbiology & Immunology，2011，344(1)：269.
[16]Rivera SM，Padiernos RBC，Abella EA，et al.Molecular characterization of the lymphocyte activation gene-3（LAG-3，CD223) of swamp-and riverine-type water buffaloes（Bubalus bubalis)［J］.Japanese Journal of Veterinary Research，2017，65(2)：65-74.
[17]Triebel F，Jitsukawa S，Baixeras E，et al.LAG-3，a novel lymphocyte activation gene closely related to CD4［J］.Journal of Experimental Medicine，1990，171(5)：1393-1405.
[18]Huard B，Mastrangeli R，Prigent P，et al.Characterization of the major histocompatibility complex class Ⅱ binding site on LAG-3 protein［J］.Proc Natl Acad Sci USA，1997，94(11)：5744-5749.
[19]Fourcade J，Sun Z，Pagliano O，et al.CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1［J］.Cancer Research，2012，72(4)：887.
[20]Ezinne CC，Yoshimitsu M，White Y，et al.HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection［J］.PLoS One，2014，9(2)：e87631.
[21]Baitsch L，Legat A，Barba L，et al.Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation，antigen-specificity and anatomical localization［J］.PLoS One，2012，7(2)：e30852.
[22]Baitsch L，Baumgaertner P，Devêvre E，et al.Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients［J］.Journal of Clinical Investigation，2011，121(6)：2350.
[23]Woo SR，Turnis ME，Goldberg MV，et al.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape［J］.Cancer Research，2012，72(4)：917-927.
[24]Grosso JF，Kelleher CC，Harris TJ，et al.LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems［J］.Journal of Clinical Investigation，2007，117(11)：3383-3392.
[25]Matsuzaki J，Gnjatic S，Mhawechfauceglia P，et al.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer［J］.Proceedings of the National Academy of Sciences of the United States of America，2010，107(17)：7875-7880.
[26]Huang RY，Francois A，Mcgray AR，et al.Compensatory upregulation of PD-1，LAG-3，and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer［J］.Oncoimmunology，2017，6(1)：e1249561.
[27]Ma QY，Huang DY，Zhang HJ，et al.Function and regulation of LAG3 on CD4+CD25-T cells in non-small cell lung cancer［J］.Experimental Cell Research，2017，360(2)：358-364.
[28]Hald SM，Rakaee M，Martinez I，et al.LAG-3 in non-small-cell lung cancer：Expression in primary tumors and metastatic lymph nodes is associated with improved survival［J］.Clinical Lung Cancer，2017，19(3)：249-259.
[29]Li FJ，Zhang Y，Jin GX，et al.Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+，T cell in HCC patients［J］.Immunology Letters，2013，150(1-2)：116-122.
[30]Camisaschi C，Casati C，Rini F，et al.LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites［J］.Journal of Immunology，2010，184(11)：6545.
[31]Gagliani N，Magnani CF，Huber S，et al.Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells［J］.Nature Medicine，2013，19(6)：739-746.
[32]Chen J，Chen Z.The effect of immune microenvironment on the progression and prognosis of colorectal cancer［J］.Medical Oncology，2014，31(8)：1-8.
[33]Vasen HF，Watson P，Mecklin JP，et al.New clinical criteria for hereditary nonpolyposis colorectal cancer（HNPCC，Lynch syndrome) proposed by the International Collaborative Group on HNPCC［J］.Gastroenterology，1999，116(6)：1453.
[34]Sijmons RH，Hofstra RM.Clinical aspects of hereditary DNA mismatch repair gene mutations［J］.DNA Repair，2015(38)：155-162.
[35]Losa NL，Cruise M，Tam A，et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints［J］.Cancer Discovery，2015，3(S2)：43-51.
[36]Becht E，Giraldo NA，Germain C，et al.Chapter four-immune contexture，immunoscore，and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers［J］.Advances in Immunology，2016，130：95-190.
[37]Park JH，Powell AG，Roxburgh CS，et al.Mismatch repair status in patients with primary operable colorectal cancer：Associations with the local and systemic tumour environment［J］.Br J Cancer，2016，114(5)：562-570.
[38]Sloan EA，Ring KL，Willis BC，et al.PD-L1 expression in mismatch repair-deficient endometrial carcinomas，including lynch syndrome-associated and mlh1 promoter hypermethylated tumors［J］.American Journal of Surgical Pathology，2017，41(3)：326.
[39]Sharma P，Allison JP.The future of immune checkpoint therapy［J］.Science，2015，348(6230)：56.
[40]Lee V，Murphy A，Le DT，et al.Mismatch repair deficiency and response to immune checkpoint blockade［J］.Oncologist，2016，21(10)：1200-1211.
[41]Legat A，Maby-El HH，Baumgaertner P，et al.Vaccination with LAG-3Ig（IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients-report of a phase I/Ⅱa clinical trial［J］.Clinical Cancer Research，2015，22(6)：1330-1340.
[42]Brignone C，Gutierrez M，Mefti F，et al.First-line chemoimmunotherapy in metastatic breast carcinoma：Combination of paclitaxel and IMP321（LAG-3 Ig) enhances immune responses and antitumor activity［J］.Journal of Translational Medicine，2010，8(1)：71.
[43]Romano E，Michielin O，Voelter V，et al.MART-1 peptide vaccination plus IMP321（LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion：Results of a phase I trial［J］.Journal of Translational Medicine，2014，12(1)：97.